Should go to 9 by the end of the week. Immune therapy research which will eventually cure cancer. It is in Clinical studies and looking good! Up 40% yesterday at its peak. On Tuesday IBRX said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related to its supplemental biologics license application for Anktiva in papillary non-muscle invasive bladder cancer.